Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$1.75 ▲ +0.05
(+2.94%)
MKT CAP: $5.2M • VOL: 5.7K
52W L $1 52W H $8
CDIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.8K | $34.9K | $17.1K |
| YoY Revenue Growth % | -57.5% | +104.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.5M | -$8.4M | -$7.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$6.5M | -$8.4M | -$8.4M |
| EBITDA (Normalized) | -$6.3M | -$8.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.7M | -$5.0M | -$5.7M |
| Capital Expenditures (CapEx) | $187.3K | $214.8K | — |
| Free Cash Flow (FCF) | -$5.9M | -$5.2M | -$5.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $0 | $0 | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.0M | $9.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CDIO.